Cover Image
市場調查報告書

美國的中樞神經系統(CNS)疾病治療藥的開發平台分析

US CNS Disorders Drug Pipeline Insight 2014

出版商 PNS Pharma 商品編碼 311224
出版日期 內容資訊 英文 1700 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的中樞神經系統(CNS)疾病治療藥的開發平台分析 US CNS Disorders Drug Pipeline Insight 2014
出版日期: 2014年08月01日 內容資訊: 英文 1700 Pages
簡介

美國的中樞神經系統(CNS)疾病市場是醫藥品產業中最大的一個部門。CNS疾病件數正在以驚人速度成長的同時,卻沒有滿足市場要件的可利用治療法。美國市場佔全球CNS疾病治療藥的55%以上的佔有率。

本報告提供美國的中樞神經系統(CNS)疾病治療藥開發趨勢相關調查,詳細為您彙整CNS疾病的發病數,市場的影響因素,市場課題等分析,疾病區分·階段·各企業的開發平台狀況,上市藥臨床簡介等資訊。

第1章 中樞神經系統(CNS)疾病:簡介

第2章 美國的中樞神經系統(CNS)疾病市場概要

  • 市場概要
  • 臨床實驗平台的考察

第3章 美國的中樞神經系統(CNS)疾病的發病數:不同疾病

  • 老年癡呆症
  • 多發性硬化症
  • 癲癇
  • 帕金森氏症
  • 偏頭痛
  • 亨丁頓舞蹈症
  • 思覺失調症
  • 焦慮症
  • 失眠症
  • 躁鬱症
  • ADHD

第4章 美國的中樞神經系統(CNS)疾病市場力學

  • Plus的市場參數
  • 市場課題
  • 未來的成長機會

第5章 美國的CNS疾病治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第6章 美國的老年癡呆症治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第7章 美國的多發性硬化症治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第8章 美國的帕金森氏症治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第9章 美國的CNS疾病/ 神經退化性疾病治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第10章 美國的癲癇治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第11章 美國的偏頭痛治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第12章 美國的亨丁頓舞蹈症治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第13章 美國的神經性疼痛的臨床實驗平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第14章 美國的思覺失調症的臨床試驗的考察:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第15章 美國的睡眠障礙治療藥的開發平台:階段·各企業

  • 臨床實驗平台的考察:階段·各企業
  • 上市藥臨床簡介

第16章 競爭環境

  • Alkermes
  • Allergan
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical
目錄

The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

New technology including advancements in stem cell therapy and of nanotechnology is expected to drive the growth of the CNS market. Nanotechnology in the form of the nanomaterials for wound care, drug delivery and immunomodulation is specifically seen as a positive influence on CNS therapy that is expected to open growth opportunities. While each of these therapeutic subcategories are served by established treatments there are certain markets segments with significant unmet medical needs still remain, indicating potential in these areas. There are newer treatment methodologies under development such as that using stem cell therapy and of nanotechnology that seek to address these opportunities.

The rapid advances in the R&D segment, many novel drugs are currently available for the treatment of CNS disorders. Industry related to CNS drug delivery system has also got a boost due to rapid advancement of CNS disorders market. Given the magnitude of number of patients and demand for better drugs is going to push pharmaceutical companies for significant investments. Changing life-style is one the main contributor of CNS disorders in US. Increased longevity and ageing population along with launch of novel drugs will drive the growth of CNS disease market in future.

"US CNS Disorders Drug Pipeline Insight 2014" Report Highlight:

  • Market Overview & Incidence by Disease
  • CNS Disorder Market Dynamics
  • CNS Disorder Pipeline by disease, Phase & Company
  • CNS Disorder Pipeline: 1083 Drugs in Pipeline
  • Majority CNS Drugs in Preclinical Phase: 396 Drugs
  • Majority CNS Drugs for Neurodegenerative Disorders: 228 Drugs in Pipeline
  • CNS Disorder Market Drugs: 109 Drugs
  • Majority CNS Drugs Marketed for Epilepsy: 24 Drugs

Table of Contents

1. Introduction to Central Nervous System (CNS) Disorder

2. US Central Nervous System (CNS) Disorder Market Overview

  • 2.1 Market Overview
  • 2.2 Clinical Pipeline Insight

3. US Central Nervous System (CNS) Disorder Incidence by Disease

  • 3.1 Alzheimer's Disease
  • 3.2 Multiple Sclerosis
  • 3.3 Epilepsy
  • 3.4 Parkinson Disease
  • 3.5 Migraine
  • 3.6 Huntington's disease
  • 3.7 Schizophrenia
  • 3.8 Anxiety
  • 3.9 Insomnia
  • 3.10 Bipolar Disorder
  • 3.11 ADHD

4. US Central Nervous System (CNS) Disorder Market Dynamics

  • 4.1 Favorable Market Parameters
  • 4.2 Market Challenges
  • 4.3 Future Growth Opportunity

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company

  • 5.1 Clinical Pipeline Insight by Phase & Company
  • 5.2 Marketed Drugs Clinical Profile

6. US Alzheimer's Disease Drug Pipeline by Phase & Company

  • 6.1 Clinical Pipeline Insight by Phase & Company
  • 6.2 Marketed Drug Clinical Profile

7. US Multiple Sclerosis Drug Pipeline by Phase & Company

  • 7.1 Clinical Pipeline Insight by Phase & Company
  • 7.2 Marketed Drug Clinical Profile

8. US Parkinson's Disease Drug Pipeline by Phase & Company

  • 8.1 Clinical Pipeline Insight by Phase & Company
  • 8.2 Marketed Drug Clinical Profile

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company

  • 9.1 Clinical Pipeline Insight by Phase & Company
  • 9.2 Marketed Drug Clinical Profile

10. US Epilepsy Drug Pipeline by Phase & Company

  • 10.1 Clinical Pipeline Insight by Phase & Company
  • 10.2 Marketed Drug Clinical Profile

11. US Migraine Drug Pipeline by Phase & Company

  • 11.1 Clinical Pipeline Insight by Phase & Company
  • 11.2 Marketed Drug Clinical Profile

12. US Huntington's Disease Drug Pipeline by Phase & Company

  • 12.1 Clinical Pipeline Insight by Phase & Company
  • 12.2 Marketed Drug Clinical Profile

13. US Neuropathic Pain Clinical Pipeline by Phase & Company

  • 13.1 Clinical Pipeline Insight by Phase & Company
  • 13.2 Marketed Drug Clinical Profile

14. US Schizophrenia Clinical Trial Insight by Phase & Company

  • 14.1 Clinical Pipeline Insight by Phase & Company
  • 14.2 Marketed Drug Clinical Profile

15. US Sleep Disorders Drug Pipeline by Phase & Company

  • 15.1 Clinical Pipeline Insight by Phase & Company
  • 15.2 Marketed Drug Clinical Profile

16. Competitive Landscape

  • 16.1 Alkermes
  • 16.2 Allergan
  • 16.3 AstraZeneca
  • 16.4 Biogen Idec
  • 16.5 Bristol-Myers Squibb
  • 16.6 Eli Lilly
  • 16.7 GlaxoSmithKline
  • 16.8 Merck
  • 16.9 Novartis
  • 16.10 Pfizer
  • 16.11 Roche
  • 16.12 Sanofi
  • 16.13 Sunovion Pharmaceuticals
  • 16.14 Teva Pharmaceutical
  • Figure 2-1: US - CNS Disorders Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-2: US - CNS Disorders Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-3: US - CNS Disorder Drugs Clinical Pipeline by Disease (%), 2014
  • Figure 2-4: US - CNS Disorder Drugs Clinical Pipeline by Disease (Number), 2014
  • Figure 2-5: US - CNS Disorder Drugs in Research Phase by Disease (%), 2014
  • Figure 2-6: US - CNS Disorder Drugs in Research Phase by Disease (Number), 2014
  • Figure 2-7: US - CNS Disorder Drugs in Preclinical Phase by Disease (%), 2014
  • Figure 2-8: US - CNS Disorder Drugs in Preclinical Phase by Disease (Number), 2014
  • Figure 2-9: US - CNS Disorder Drugs in Clinical Phase by Disease (%), 2014
  • Figure 2-10: US - CNS Disorder Drugs in Clinical Phase by Disease (Number), 2014
  • Figure 2-11: US - CNS Disorder Drugs in Phase-0 by Disease (%), 2014
  • Figure 2-12: US - CNS Disorder Drugs in Phase-0 by Disease (Number), 2014
  • Figure 2-13: US - CNS Disorder Drugs in Phase-I by Disease (%), 2014
  • Figure 2-14: US - CNS Disorder Drugs in Phase-I by Disease (Number), 2014
  • Figure 2-15: US - CNS Disorder Drugs in Phase-I/II by Disease (%), 2014
  • Figure 2-16: US - CNS Disorder Drugs in Phase-I/II by Disease (Number), 2014
  • Figure 2-17: US - CNS Disorder Drugs in Phase-II by Disease (%), 2014
  • Figure 2-18: US - CNS Disorder Drugs in Phase-II by Disease (Number), 2014
  • Figure 2-19: US - CNS Disorder Drugs in Phase-II/III by Disease (%), 2014
  • Figure 2-20: US - CNS Disorder Drugs in Phase-II/III by Disease (Number), 2014
  • Figure 2-21: US - CNS Disorder Drugs in Phase-III by Disease (%), 2014
  • Figure 2-22: US - CNS Disorder Drugs in Phase-III by Disease (Number), 2014
  • Figure 2-23: US - CNS Disorder Drugs in Preregistration Phase by Disease (%), 2014
  • Figure 2-24: US - CNS Disorder Drugs in Preregistration Phase by Disease (Number), 2014
  • Figure 2-25: US - CNS Disorder Drugs in Registration Phase by Disease (%), 2014
  • Figure 2-26: US - CNS Disorder Drugs in Registration Phase by Disease (Number), 2014
  • Figure 2-27: US - Marketed CNS Disorder Drugs by Disease (%), 2014
  • Figure 2-28: US - Marketed CNS Disorder Drugs by Disease (Number), 2014
  • Figure 2-29: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-30: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-31: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-32: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-33: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-34: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-35: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-36: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-37: US - Epilepsy Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-38: US - Epilepsy Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-39: US - Migraine Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-40: US - Migraine Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-41: US - Huntington's Disease Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-42: US - Huntington's Disease Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-43: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-44: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-45: US - Schizophrenia Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-46: US - Schizophrenia Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-47: US - Sleep Disorders Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-48: US - Sleep Disorders Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 3-1: US - Alzheimer's Disease Incidence (Million), 2013-2020
  • Figure 3-2: US - Multiple Sclerosis Incidence ('000), 2013-2020
  • Figure 3-3: US - Epilepsy Incidence (Million), 2013-2020
  • Figure 3-4: US - Parkinson's Disease Incidence (Million), 2013-2020
  • Figure 3-5: US - Migraine Incidence (Million), 2013-2020
  • Figure 3-6: US - Huntington's Disease Incidence ('000), 2013-2020
  • Figure 3-7: US - Schizophrenia Disease Incidence (Million), 2013-2020
  • Figure 3-8: US - Anxiety Disorder Incidence (Million), 2013-2020
  • Figure 3-9: US - Insomnia Incidence (Million), 2013-2020
  • Figure 3-10: US - Bipolar Disorder Incidence (Million), 2013-2020
  • Figure 3-11: US - ADHD Incidence (Million), 2013-2020
Back to Top